SLC18A2 and thanatophoric dysplasia: Among the most promising new therapies for TD are the vesicular monoamine transporter 2 (VMAT2) inhibitors, a new drug class including valbenazine and deutetrabenazine.12, 13, 14, 15, 16, 17